Laura Lovett
The company's smart insulin pen, dubbed the InPen, is slated to become part of Medtronics diabetes portfolio.
The system was designed to give users advice about their brushing habits.
Dr. Lee also dives into the challenges and opportunities of digital health in providing equitable healthcare.
The new round was led by European Bank for Reconstruction and Development and Health Capital.
The deal is valued at roughly $4.7 billion.
Barriers to adoption include hearing issues, lack of tech abilities and visual difficulties.
Each Livongo share will be converted Teladoc stock at a 0.5920 exchange rate, plus an additional $11.44 in cash per stock.
The companies will also be looking into using Eko's tech in clinical trials.
The company said the product will give customers information about their genetic risk for certain diseases.
The new service will let patients communicate with general practitioners, mental health clinicians and specialists.